Brought to you by 
Idec and Eisai in autoimmune antibody collaboration
13 Jul 1999
Executive Summary
Japanese drug company Eisai and Idec Pharmaceuticals (immunotherapies for cancer and autoimmune diseases) will collaborate to develop Idec's Primatized antibodies to the gp39 antigen into therapies for antibody-mediated autoimmune disorders.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Idec and Eisai in autoimmune antibody collaboration
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice